Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
  • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
  • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
  • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
  • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6953—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a fibre, a textile, a slab or a sheet
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
  • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
  • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
  • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
  • A61K49/0043—Fluorescein, used in vivo
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
  • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
  • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
  • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
  • A61L15/42—Use of materials characterised by their function or physical properties
  • A61L15/44—Medicaments
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L27/54—Biologically active materials, e.g. therapeutic substances
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
  • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
  • A61L29/16—Biologically active materials, e.g. therapeutic substances
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
  • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L31/16—Biologically active materials, e.g. therapeutic substances
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
  • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
  • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids

Definitions

• the invention relates to medical devices and other pharmacologically useful solid supports that are covalently bond to a multiplicity of drug molecules through covalent linkers that release drug through controlled beta elimination reactions.
• compositions and methods have been described for controlled release of drugs covalently coupled to macromolecules, such as polyethylene glycol (PEG), in order to enhance pharmaceutical properties, such as half-life, stability, solubility, tolerability, and safety.
• drug moieties are coupled to macromolecules through a permanent linker, but this approach is limited by at least two factor: 1) the linker must be attached to the drug moiety at a site that does not hinder biological activity, and 2) permanent conjugates generally cannot cross the cell membrane, so the approach may only be feasible for extracellular drug targets.
• covalently bound drug-macromolecule conjugates employ PEG as a releasable carrier of the drug or prodrug.
• the drug is attached to the carrier by an ester or carbonate linkage that can be cleaved by esterase-catalyzed hydrolysis.
• ester or carbonate linkage that can be cleaved by esterase-catalyzed hydrolysis.
• Examples are PEG-camptothecin, PEG-SN38, PEG-irinotecan and PEG-docetaxel. Additional adaptations have been made to accommodate amine-containing drugs whereby a PEG moiety is connected by a cleavable ester to a self-immolating carbamate. This technology has been applied to peptides and proteins as well as to daunorubicin, amphotericin, Ara-C and other small molecules. However, drug release rates in these cases is unpredictable and difficult to adjust, because esterase activity varies between species and individuals, and certain compartments are esterase-deficient (e.g. , topical, intra-ocular, interstitial areas).
• PCT publication WO2009/158668 describes drug-macromolecule conjugates wherein the drug is released through a beta-elimination mechanism, and wherein the rate of beta-elimination is controlled by a trigger independent of the macromolecule itself. This solves a problem left unsolved in the prior art.
• the release mechanism set forth in the '668 PCT publication has not been applied to instances where a multiplicity of drugs is coupled covalently, but releasably, to the surface of or interstices of solid supports.
• the present invention provides for drug-solid support conjugates wherein the drug is released at a controlled rate from the solid support.
• this approach offers a means whereby the coupled drug is protected from hydrolysis by the presence of a protective polymer, such as PEG, on different sites at the surface or interstices of the solid support.
• the invention provides conjugates of drugs, growth factors, or other biological agents such as viral delivery agents, with solid supports that are useful in physiology and medicine, comprising cleavable linkers that allow for subsequent release of the drugs at controlled rates under physiological conditions, as well as solid supports comprising the , cleavable linkers, synthetic intermediates, and methods for the preparation and use of the above.
• a linker is covalently bound to multiple sites on the solid support, and each linker is in turn coupled to an appropriate drug or prodrug. The drug or prodrug is then released at the desired rate through a beta-elimination reaction at physiological pH.
• the drug sites on the support may be contained within a protective layer of polymer bound to adjacent sites on the solid support.
• n 0 or 1 ;
• R 1 and R 2 is independently CN; N0 2 ;
• R 3 is H or optionally substituted alkyl
• heteroaryl or heteroarylalkyl each optionally substituted;
• R 4 is optionally substituted alkyl
• aryl or arylalkyl each optionally substituted; or heteroaryl or heteroarylalkyl, each optionally substituted;
• R 1 and R 2 may be joined to form a 3-8 membered ring
• R 1 and R 2 may be H or may be alkyl, arylalkyl or heteroarylalkyl, each optionally substituted;
• each R s is independently H or is alkyl, alkenylalkyl, alkynylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, each optionally substituted;
• D is a residue of a drug or prodrug coupled through O, S, or N;
• Y is absent and X is O or S;
• Y is NBCH 2 and X is O;
• B is alkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, each optionally substituted;
• R 1 , R 2 , R 5 or B is coupled to a solid support.
• Said solid support may also be further coupled to a protective inert polymer.
• the invention is directed to a solid support coupled to a multiplicity of substituents of the formula
• n 0 or 1 ;
• R 1 and R 2 is independently CN; N0 2 ;
• R is H or optionally substituted alkyl
• heteroaryl or heteroarylalkyl each optionally substituted;
• R 4 is optionally substituted alkyl
• aryl or arylalkyl each optionally substituted; or heteroaryl or heteroarylalkyl, each optionally substituted;
• R 1 and R 2 may be joined to form a 3-8 membered ring
• R 1 and R 2 may be H or may be alkyl, arylalkyl or heteroarylalkyl, each optionally substituted;
• each R 5 is independently H or is alkyl, alkenylalkyl, alkynylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, each optionally substituted;
• D is a residue of a drug or prodrug coupled through O, S, or N;
• Y is absent and X is O or S;
• Y is NBCH 2 and X is O; wherein B is alkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, each optionally substituted; and
• the solid support may also comprise a multiplicity of protective inert polymers, such as PEG.
• the solid support may be, for example, a stent, a hydrogel, a catheter, a wound dressing, an implant, a plaster, an orthopedic device, or a dental prosthesis.
• the invention is directed to methods to prepare the compositions of the invention, and methods to employ them in medical/veterinary/physiological procedures. It also includes intermediates in the synthesis of formulas (1) and (2).
• the invention further includes "precursor" molecules identical to formula (1) or (2) in which one of R 1 , R 2 , R 5 or B is coupled to the solid support, except that in lieu of a drug or prodrug residue a leaving group is present.
• the solid support thus has substituents of formula (3) (3)
• R , R , R , X, Y and m are as defined as in formula (1) or (2);
• L is a nucleofuge for coupling the drug or prodrug to the remainder of the molecule.
• the present invention provides for a drug-solid support conjugate, wherein the drug is connected to the solid support via a linker, the drug molecule is attached to the linker through an O, S, or N, and wherein the drug is released from the conjugate under physiological conditions through a beta-elimination reaction.
• the present invention provides for compounds of formula (4)
• Figure 1 shows the general nature of release of drug or prodrug by ⁇ -elimination.
• Figure 2 is a graph showing the relationship of free energy to half-life for release of label from substituted ⁇ -elimination compounds through study of a model system, as described in Example 1.
• Figure 3 is a graph showing the free energy correlation between Hammett sigma values and rate of release of label by ⁇ -elimination as described in Example 2.
• Figure 4 shows the results of Example 33 as a comparison of rates of release at 37°C, pH 8.4.
• Figure 5 shows a comparison of in vivo and in vitro release rates of drugs as a function of the Hammett constants associated with the trigger on a series of PEG-conjugated linkers wherein Rl is optionally substituted phenyl S02, R2 is H and the drug is fluorescein.
• the rate of beta-elimination from the linker is dependent on the phenyl substituent, with electron- withdrawing substituents (positive sigma: CF3, CI) giving faster rates and electron-donating substituents (negative sigma: Me, OMe) giving slower rates.
• the rate correlation is observed both in vitro and in vivo (measured in rat).
• a solid support which provides a controlled release of such a drug (or prodrug) may be termed an "implant" or a “topical applicator.”
• Such implants and topical applicators may take many forms, including vascular grafts and neural probes.
• an intravascular stent For instance, one of the most common instances of an "implant" that serves both a mechanical purpose and a drug dispensing purpose is an intravascular stent.
• Such stents may be metallic or polymeric and in many instances are designed to release drugs that have been noncovalently entrapped in a polymeric coating.
• Antiproliferative agents which are helpful in preventing restenosis may be included as well as thromboxane inhibitors angiotensin converting enzyme inhibitors, and prostacyclin mimetics.
• such drugs may be covalently coupled to either polymeric or metallic stents using the linkers and methods of the invention.
• solid supports include hydrogels, including collagen hydrogels that are commonly used in eyedrops and eardrops. These, too, may be linked to suitable ophthalmic and otological agents using the invention methods and compositions. Anti-glaucoma drugs as well as drugs designed to treat macular degeneration, for example, may be thus coupled.
• catheters Another commonly employed medical device which is a solid support is a catheter.
• catheters especially those that are designed for long residence times, may be coupled to drugs appropriate for treatment, but also to antibiotics to prevent infection.
• Hydrogels may also be used as implants to support stem cell therapies, and release of growth factors for such stem cells through the methods of the invention by linking them to the hydrogel matrix is an aspect of the invention.
• the support may also comprise polylactic-glycolic acid (PLGA) polymers.
• PLGA polylactic-glycolic acid
• PLGA is a common choice in the production of a variety of biomedical devices, such as grafts, sutures, implants, prosthetic devices, and nanoparticles. Free carboxylate groups can be derivatized.
• implants intended to provide anti-arthritic drugs directly to joints in rheumatoid arthritis patients.
• Topical applications include surgical dressings and plasters where the drugs are released externally, and may be designed for treatment of surface wounds or for transdermal entry into the body.
• Still other types of solid supports include orthopedic devices which may profitably be coupled to bone growth factors, such as bone morphogenic factor, and dental matrices which may be designed to supply suitable antibiotics and growth factors.
• solid support any material that independently exists as a solid, although the surface may not be smooth or hard, and the solid may be flexible.
• hydrogels are included as well as surgical dressings, bandages, physical objects, and the like.
• the drug conjugate of formula (1) or (2) is designed to control the pharmacokinetics of the drug or prodrug, the residue of which when coupled to the remainder of the molecule is designated as "D".
• the mechanism whereby the drug or prodrug is released is shown in Figure 1.
• the rate of release is controlled according to a pH dependent ⁇ -elimination mechanism.
• the groups R 1 and R 2 are selected to provide the desired acidity, and thus, reactivity, of the intervening proton in R ⁇ CH-R 2 , providing control over the rate of drug or prodrug release.
• the properties of R 1 and R 2 may be modulated by the optional addition of electron-donating or electron-withdrawing substituents, for example, in aryl moieties contained therein.
• R 1 or R 2 can behave as the "trigger" shown in Figure 1.
• the nature of the "trigger” controls the acidity of the intervening proton in R ⁇ CH-R 2 , which, when released, permits the electron pair thus freed to effect ⁇ -elimination as shown in Figure 1 for compounds wherein Y is absent; the first step of the reaction is common to that set forth below when Y is NBCH 2 .
• the product acids are typically highly unstable, and further decompose to release C0 2 or COS, or C0 2 , B-NH 2 , and
• H 2 C 0, as well as D-H, depending on the nature of X and Y.
• the degree to which the R 1 and/or R 2 groups activate the adjacent C-H bond may be expressed by the resulting acidity of the C-H bond; this acidity may in turn be expressed as the pK a of the C-H bond, wherein a lower p a denotes a more acidic, more readily ionized C-H bond.
• Listings of approximate pK a values for various groups are common in the art, for example in Bordwell, F. G., "Equilibrium acidities in dimethyl sulfoxide solution," Accounts of
• suitably activating groups include, but are not limited to, optionally substituted aryls, optionally substituted heteroaryls, optionally substituted alkenes, optionally substituted alkynes, sulfones,
• the ring may form part of a larger cyclic structure, optionally substituted, for example
• Substituents on the R 1 and/or R 2 groups may optionally be added to provide further control over the acidity of the adjacent C-H, and thus the rate of the beta-elimination reaction.
• electron-withdrawing substituents will increase the rate of the beta-elimination reaction, while electron-donating substituents will decrease the rate of the beta-elimination reaction.
• the electronic effect of various substituents is well-known in the art, and may be expressed for example as linear free-energy (Hammett) relationships.
• aromatic systems for example substituted aryl, heteroaryl, arylketone, heteroarylketone, arylsulfone,
• an aryl ring R 1 is substituted with an "electron-donating group" is substituent that will result in a decrease in the acidity of the adjacent benzylic-type C- H bond.
• suitable electron-donating substituents include but are not limited to, alkyl, alkoxy, alkylthio, silyl amino, alkylamino, and dialkylamino. Substitution of an aryl ring with one or more "electron- withdrawing groups" results in an increase in the acidity of the adjacent benzylic-type proton.
• Non-hydrogen electron-donating or electron-withdrawing substituents may be present in multiple positions on rings to which they are bound. While, for convenience, in most examples, only a single occurrence of a non-hydrogen substituent on a single ring is shown, multiple substituents may also be present and are within the scope of the invention. The substituents may be the same or different.
• CH 2 CH +0.05 -0.02 N0 2 +0.71 +0.78
• the solid supports may be coupled to formulas (1) or (2) through additional
• the additional connectors are bifunctional organic compounds. Many such connectors are commercially available, for example from Pierce Chemical Co, Rockford, IL.
• Various bifunctional connecters are well known in the art, including dicarboxylic acids or anhydrides, diamines, or heterobifunctional connecters.
• heterobifunctional connecters include, for example, those having a succinimidyl ester ("NHS”) and an alkyne or cycloalkyne (for example, DBCO-NHS), a maleimide and an NHS, or similar molecules.
• NHS succinimidyl ester
• DBCO-NHS alkyne or cycloalkyne
• the selection of the connector will, of course, depend on the nature of the functional groups on the substituents on the macromolecule, the drug, and on the intermediates corresponding to
• alkyl includes linear, branched, or cyclic saturated hydrocarbon groups of 1-8 carbons, or in some embodiments 1-6 or 1-4 carbon atoms.
• alkoxy includes alkyl groups bonded to oxygen, including methoxy, ethoxy, isopropoxy, cyclopropoxy, cyclobutoxy, and similar.
• alkenyl includes non-aromatic unsaturated hydrocarbons with carbon- carbon double bonds.
• alkenyl (C 2 ) is meant a mono-, di-, tri-, or tetra-substituted carbon-carbon double bond of any geometric configuration.
• alkynyl includes non-aromatic unsaturated hydrocarbons with carbon- carbon triple bonds.
• alkynyl (C 2 ) is meant a mono- or di-substituted carbon- carbon triple bond.
• aryl includes aromatic hydrocarbon groups of 6-18 carbons, preferably 6-10 carbons, including groups such as phenyl, naphthyl, and anthracenyl.
• heteroaryl includes aromatic rings comprising 3-15 carbons containing at least one N, O or S atom, preferably 3-7 carbons containing at least one N, O or S atom, including groups such as pyrrolyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, quinolyl, indolyl, indenyl, and similar.
• alkenyl, alkynyl, aryl or heteroaryl moieties may be coupled to the remainder of the molecule through an alkylene linkage.
• the substituent will be referred to as alkenylalkyl, alkynylalkyl, arylalkyl or heteroarylalkyl, indicating that an alkylene moiety is between the alkenyl, alkynyl, aryl or heteroaryl moiety and the molecule to which the alkenyl, alkynyl, aryl or heteroaryl is coupled.
• halogen includes bromo, fluoro, chloro and iodo.
• heterocyclic ring refers to a 4-8 membered aromatic or non-aromatic ring comprising 3-7 carbon atoms and at least one N, O, or S atom.
• examples include piperidinyl, piperazinyl, tetrahydropyranyl, pyrrolidine, and tetrahydrofuranyl, as well as the exemplary groups provided for the term "heteroaryl" above.
• a "nucleofuge” is a leaving group that takes with it the electron pair by which it is bonded.
• Exemplary nucleoiuges are halogen, OH, alkoxy, hydroxysuccinimidyl, arylsulfonate, alkylsulfonate, or R 2 S + , wherein each R is independently alkyl, aryl, or heteroaryl.
• the terms "protein” and “peptide” are used interchangeably regardless of chain length, and these terms further include pseudopeptides which comprise linkages other than amide linkages, such as CH 2 N3 ⁇ 4 linkages as well as peptidomimetics.
• nucleic acids and “oligonucleotides” are also used interchangeably regardless of chain length.
• the nucleic acids or oligonucleotides may be single-chain or duplexed or may be DNA, RNA, or modified forms thereof with altered linkages, such as phosphodiesters, phosphoramidates, and the like.
• these terms also include those with side chains not found in nature in the case of proteins as well as pseudopeptide bonds and bases not found in nature in the case of nucleic acids as well as backbone modifications such as peptide nucleic acids.
• small molecule in the context of drugs is a term well understood in the art, and is meant to include compounds other than proteins and nucleic acids that either are synthesized or are isolated from nature and in general do not resemble proteins or nucleic acids. Typically, they have molecular weights ⁇ 1,000, although there is no specific cutoff recognized. Nevertheless, the term is well understood in the fields of pharmacology and medicine.
• a wide variety of drugs may be included as the embodiment of D. Each of these drugs will be coupled through a nitrogen, oxygen or sulfur to the remainder of the molecule.
• suitable drugs will be those that possess a hydroxy, thiol, or free NH to allow for coupling to the linker.
• more than 50% of approved small molecule drugs possess an aliphatic hydroxyl or thiol group or a phenolic hydroxyl group, and more than 40% contain a primary or secondary amine, sulfonamide, amide, imide, or heterocyclic NH (such as a pyrrole or indole).
• most approved drugs would be amenable to conjugation according to the invention.
• the invention contemplates conjugation of a drug moiety through a primary or secondary hydroxyl, a phenol, a heteroaryl-OH, a thiol, a thiophenol or a heteroaryl-SH; or a "non-basic N".
• non-basic N refers to a nitrogen that is part of an NH group in a free drug molecule DH, wherein the NH is characterized by having a pKa less than or equal to about 20.
• the non-basic N is a member of a primary or secondary amide, a primary or secondary sulfonamide, an imide, or a heteroaryl NH (such as that present in pyrrole, pyrimidine, indole, or purine) (collectively, "non-basic NH" groups).
• Suitable drugs include those for human or veterinary use including, but not limited to, antidiabetic drugs; growth promoters; antibacterials including aminoglycosides, penicillins, cephalosporins, macrolides and peptides, trimethoprim, piromidic acid, and sulfamethazine; analgesic and anti-inflammatory drugs, antiallergic and antiasthmatic drugs, antihypercholesterolemic drugs, beta-adrenergic blockers and antihypertensive drugs, antineoplastic drugs, and antiviral drugs.
• drugs include alcohols such as paclitaxel and analogues, epothilones and analogues, camptothecin and analogues such as irinotecan, and nucleosides such as 5-fluorouracil and capecitabine.
• the drug is a peptide comprising a serine residue.
• the drug is a small molecule comprising an arylol group; examples of such drugs include SN-38, etilefrine, prenalterol, and estradiol.
• the drug is a peptide comprising a tyrosine residue.
• the drug may be a small molecule comprising a thiol group.
• examples of such drugs include penicillamine, captopril, and enalapril.
• the drug may be a small molecule comprising a thioaryl or thioheteroaryl group; examples of such drugs include 6-mercaptopurine.
• the drug may be a small molecule or peptide comprising a primary or secondary amide (such as a pyroglutamate residue or other amide) or sulfonamide, or a heteroaryl group such as an indole (e.g., tryptophan) or purine. Examples include thyrotropin- releasing hormone, bombesin, luteinizing hormone-releasing hormone, follicle-stimulating releasing hormone, octreotide, 5-fluorouracil and allopurinol.
• peptide drugs suitable for use in the invention include, e.g., glucagon-like peptide 1 (GLP-1), atrial natriuretic factor (ANF), and many others.
• protein drugs include immunotoxin SS1P, enzymes such as adenosine deaminase, arginase, and others, growth factors, antibodies and cytokines, for example.
• nucleic acid-based drugs include the sense strand and antisense strand of any gene from an animal, and particularly from a mammal.
• genes can be those that are already the subjects of antisense DNAs or R As, or small interfering R As that have been provided with the purpose of treating various diseases, for example genes for protein kinase C-alpha, BCL-2, ICAM-1, tumor necrosis factor alpha and the like.
• Additional examples include viral delivery agents for nucleic acids.
• precursor refers to a derivatized solid support similar to that of formula (1) or (2), but wherein rather than linked to the drug or prodrug, the linking compound is coupled to a nucleofuge for further binding to a drug or prodrug as in formula (3)
• R 2 , R 5 , X, Y and m are as defined as in formula (1) or (2); and wherein L is a nucleofuge.
• the active form of the drug is directly released from the conjugates of the invention, in some cases, it is possible to release the active drug in the form of a prodrug thereof.
• a prodrug thereof On example of such a s stem is shown below:
• M is H or is at least one suitable aryl substituent.
• drug conjugates include conjugates both of drugs and prodrugs.
• Optional substituents on any group, including the above, include halo, nitro, cyano, OR, SR, NR 2 , OCOR, NRCOR, COOR, CONR 2 , SOR, S0 2 R, SONR 2 , S0 2 NR 2 , wherein each R is independently alkyl, alkenyl, alkynyl, aryl or heteroaryl, or two R groups taken together with the atoms to which they are attached form a ring.
• Compounds of the invention contain a linkage to a solid support via one ofR ⁇ R , R , and B (formulas (1), (2), and (3)), or one ofR ⁇ R z , R J , and B comprises a functional group that allows for connection to a solid support (formula (4)).
• Suitable functional groups that allow for connection to a solid support include amino, azido, hydroxy, carboxylic acid, alkynyl, thiol, maleimido, furan, cyclopentadiene, 1,3-diene, or 1,3-dicarbonyl groups, or protected variants thereof.
• Substituents that comprise a reactive functional group include alkyl, aryl, arylalkyl, heteroaryl, heteroalkyl, or heteroarylalkyl group, substituted with a reactive chemical moiety.
• at least one of the R 1 , R 2 , R 5 , and B groups comprises a solid support or comprises one or more amino, azido, hydroxy, carboxylic acid, alkynyl, thiol, maleimido, furan, cyclopentadiene, 1,3-diene, or 1,3-dicarbonyl groups, or protected variants thereof.
• R 1 is coupled to a solid support or comprises a functional group allowing for connection to a solid support.
• R 5 is coupled to a solid support or comprises a functional group allowing for connection to a solid support.
• R 1 and R 2 together exert the most control over the release rate for the drug, though R 5 and m have some impact as well.
• R and R is hydrogen or is alkyl, arylalkyl or heteroarylalkyl and the other comprises one of the remaining embodiments set forth hereinabove.
• neither of R 1 and R 2 is hydrogen or is alkyl, arylalkyl or heteroarylalkyl.
• R may be H and R optionally substituted phenyl or both R and R may be optionally substituted phenyl.
• the substitutions on the phenyl rings may be at 1-5 positions but preferably 3 or less. If both R 1 and R 2 are optionally substituted phenyl, they need not be substituted identically, or may be identically substituted.
• Suitable substituents include alkoxy, halo, nitro, cyano and the like, for example as indicated in Table 1 above.
• R 1 and R 2 is R 6 S- R 6 S(0) -, or R 6 S(0) 2 - wherein R 6 is alkyl, substituted alkyl, dialkylamino, alkylarylarmino, diarylamino, an N-linked heterocyclic ring, aryl, substituted aryl, heteroaryl, or substituted heteroaryl.
• R 6 is alkyl, substituted alkyl, dialkylamino, alkylarylarmino, diarylamino, an N-linked heterocyclic ring, aryl, substituted aryl, heteroaryl, or substituted heteroaryl.
• the remaining member of R 1 and R 2 may then be, H, for example, or any of the alternative embodiments set forth above.
• one of R 1 and R 2 is R 6 S(0) 2 - wherein R 6 is methyl, morpholino, unsubstituted phenyl, or phenyl substituted with one or more halo, methyl, methoxy, or trifluoromethyl groups, and the other of R 1 and R 2 is H.
• one of R 1 and R 2 is phenylsulfonyl, 4-(trifluoromethyl)phenylsulfonyl, 4-chlorophenylsulfonyl, 4-methyIphenylsulfonyl, 4-methoxyphenylsulfonyl, 2,4-dimethylsulfonyl,
• R 1 and R 2 2,4,6-trimethylphenylsulfonyl, morpholinosulfonyl, or methanesulfonyl, and the other of R 1 and R 2 is H.
• R 1 and R 2 may be cyano and the other optionally selected from H or the permissible substituents set forth above, in particular phenyl optionally substituted at one or more positions, for example, with halo, CN, N0 2 , methoxy and the like.
• R 1 and R 2 is optionally substituted benzoyl and the other is hydrogen or any of the other suitable choices, such as optionally substituted phenyl.
• one of R 1 and R 2 is aminocarbonyl, such as
• one of R 1 and R 2 is any one of the particular
• R 1 and R 2 are joined to form cyclic structures, this includes groups wherein the R -C -R moiety forms a substructure such as, for example,
• Such cyclic structures may further comprise a connection to the solid support (or a functional group allowing for connection to the solid support, as in formula (4)).
• R 1 and R 2 taken together with the CH to which they are attached form unsubstituted fluorenyl or fluorenyl further comprising a connection to the solid support.
• R 1 and R 2 taken together with the CH to which they are attached form fluorenyl or fluorenyl substituted with an alkyl azide, in particular (azido-N- methyl(CH 2 ) 3-6 alkyl-amido)methyl.
• Each R 5 is independently H, or is alkyl, alkenylalkyl, alkynylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, each optionally substituted. In certain embodiments, each R 5 is H. In other embodiments, one of R 5 is H and the other is substituted alkyl or substituted phenyl. In still other embodiments, one of R 5 is H and the other comprises an azidoalkyl group.
• one of R 5 is H and the other is azido-(CH 2 ) 3-6 alkyl, monoalkylamino- (CH 2 ) 3-6 alkyl, N 3 (CH 2 ) 3-6 N(Me)CO(CH 2 ) 3-6 -, or -(CH 2 ) 3-6 -C0 H, or a protected variant thereof.
• one ofR 5 is any one of the particular embodiments described above, further comprising a solid support or a functional group allowing for connection to a solid support, and the other R 5 is H.
• one of R 5 is H and the other is phenyl- NHC(0)R y , where R y is azido-(CH 2 ) 5 -, HCC-(C3 ⁇ 4) 3 -, or (maleimido)-CH 2 CH 2 -.
• B is optionally substituted aryl, or optionally substituted heteroaryl.
• B is aryl or heteroaryl, each substituted with at least one group having a positive Hammett sigma constant (Table 1).
• B is phenyl or phenyl substituted with
• B is unsubstituted phenyl.
• B is unsubstituted phenyl or phenyl substituted with diethylaminocarbonyl, morpholinocarbonyl, or morpholinosulfonyl.
• B is phenyl, propargyl, 4-bromophenyl, 4-ethoxycarbonylphenyl, propyl, 4-(N,N-diethylcarboxamido)phenyl, 4-morpholinocarbonylphenyl, or
• B is phenyl, 4-(N,N- diethylcarboxamido)phenyl, 4-morpholinocarbonylphenyl, or 4-morpholinosulfonylphenyl.
• B is any one of the particular embodiments described above, further comprising a solid support or a functional group allowing for connection to a solid support.
• m is 0.
• X is O.
• Y is NBCH 2 .
• the present invention contemplates compounds of
• x 0, 1, 2, or 3;
• each R 10 is independently methyl, trifluoromethyl, methoxy, or halo
• B' is phenyl, optionally substituted with alkoxycarbonyl, carboxamido, sulfonamido, CN, N0 2 , or halo;
• Z' is a residue of a drug or prodrug coupled through O, S, or N or is a nucleofuge which permits such coupling;
• Spacer is linker comprising an alkyl, heteroalkyl, aryl, or aralkyl group, each optionally substituted;
• SS is a solid support or is a functional group allowing for connection to a solid support.
• the present invention contemplates solid supports of formula (2), wherein m is 0; R 1 is phenylsulfonyl, substituted phenylsulfonyl, methanesulfonyl, (R 9 ) 2 N-S0 2 , wherein R 9 is defined as for formula (2), or CN; R 2 is H; one R 5 is optionally substituted alkyl and the other R 5 is H; and B is phenyl or substituted phenyl, wherein one of R 1 , R 5 , and B further comprises a connection to the solid support.
• the compounds of formulas (1) or (2) are derived from precursors and intermediates where either the drug/prodrug or the solid support is added as the last step. Thus, in one pathway, a compound of the formula
• R 1 , R2 , R 5 or B (if present) are not yet coupled to the solid support, can be used as an intermediate.
• Either the drug/prodrug or the solid support may be coupled first. If the solid support is coupled first, the novel compounds of formula (3) wherein a solid support is coupled to one of R , R , R or B (if present) are formed.
• an intermediate containing the drug/prodrug can be first formed and then coupled to the solid support (e.g., formula (4)).
• one step in the synthesis is coupling the remainder of the molecule to the solid support; thus, intermediates are synthesized which contain functional groups in the appropriate R 1 , R 2 , R 5 or B substituents that permit such coupling.
• Methods for conjugation of the intermediates or precursors to solid supports are generally known in the art.
• an amide linkage is formed between an amino group and a carboxylic acid group; thus, a precursor or intermediate comprising an amino group can be conjugated to a solid support comprising a carboxylic acid group, or a precursor comprising a carboxylic acid group can be conjugated to a solid support comprising an amino group.
• a titanium surface is first modified with a siloxane reagent such as (3-aminopropyl)triethoxysilane (APTES), and the resulting amine-coated surface is reacted with a linker comprising a carboxylate group in the presence of a coupling reagent, for example a carbodiimide, phosphonium, or uranium reagent, to effect a carboxamide bond to the surface.
• a siloxane reagent such as (3-aminopropyl)triethoxysilane (APTES)
• the surface may first be treated with a heterobifunctional connecter, which is then reacted with a linker comprising a complimentary functional group.
• the amine-coated surface is reacted with an alkynoic acid, for example 5-hexynoic acid, under similar conditions so as to produce an alkyne-coated surface.
• the alkyne-coated surface is then coupled to an azido-linker-drug under Cu(I) catalysis to couple the linker-peptide via a 1,2,3-triazole.
• amino-coated surface is reacted with a cyclooctyne- containing carboxylic acid so as to produce a cyclooctyne-coated surface, which is coupled to an azido-linker-drug via a 1,2,3-triazole under copper-free conditions.
• the amine-coated surface is reacted with an heterobifunctional connecter comprising an N-hydroxysuccinimidyl ester or carbonate on one end and a maleimido group on the other end, for example 4-(maleimido)butyryloxy succinimide.
• an heterobifunctional connecter comprising an N-hydroxysuccinimidyl ester or carbonate on one end and a maleimido group on the other end, for example 4-(maleimido)butyryloxy succinimide.
• reagents for modification of titanium surfaces are known in the art and may be used in the present invention, for example mono-functional aminosilanes (Pegg, et al,
• a condensing agent for example a carbodiimide such as dicyclohexylcarbodiimide (DCC) or l-(3-dimethylaminopropyl)- 3-ethylcarbodiimide (EDCI), a uronium reagent such as O-benzotriazole- ⁇ , ⁇ , ⁇ ', ⁇ '- tetramethyluronium-hexafluorophosphate (HBTU), or a phosphonium reagent such as benzotriazole- 1 -yl-oxy-tris-(dimethylamino)phosphonium hexafluorophosphate (BOP).
• a condensing agent for example a carbodiimide such as dicyclohexylcarbodiimide (DCC) or l-(3-dimethylaminopropyl)- 3-ethylcarbodiimide (EDCI), a uronium reagent such as O-benzotriazo
• the carboxylic acid group may be activated for conjugation in a prior step, for example by conversion to an acid chloride using thionyl chloride or oxalyl chloride, or to an active ester such as a pentafluorophenyl ester using a carbodiimide and pentafluorophenol or an N-hydroxysuccinimidyl ester using a carbodiimide and N-hydroxysuccinimide, and the resulting activated carboxylate may then be reacted with the amine in a second step.
• the amine and carboxylic acid groups may initially be present in protected form as required for stability and/or compatibility with additional chemical transformations, and deprotected prior to the conjugation step. Amine groups may be protected as carbamates, preferably
• ert-butoxycarbonyl ( l BOC), allyloxycarbonyl (Alloc), or other carbamate groups that may be removed under neutral-to-acidic conditions.
• Carboxylic acids may be protected as esters that may be removed under neutral-to-acidic conditions, such as tert-butyl (3 ⁇ 4u), trityl (Ph 3 C), allyl (All), or methoxymethyl (MOM).
• a thioether linkage is formed between a thiol group and a maleimide group; thus, a precursor comprising thiol group can be conjugated to a solid support comprising a maleimide group, or a precursor comprising a maleimide group can be conjugated to a solid support comprising a thiol group.
• the thiol group may initially be present in protected form as required for stability and/or compatibility with additional chemical transformations, and deprotected prior to the conjugation step. Suitable protecting groups include those that may be removed under neutral-to-acidic conditions, for example tert-butyl thioethers ( l Bu) or trityl thioethers.
• a 1,2,3-triazole linkage is formed between an alkyne and an azide group; thus, a precursor comprising an alkyne group can be conjugated to a solid support comprising an azide group, or a precursor comprising an azide group can be conjugated to a solid support comprising an alkyne group.
• the conjugation reactions may be performed under metal catalysis, typically using copper or ruthenium, or may be performed in the absence of catalyst using an activated alkyne such as a cyclo-octyne.
• an enamino-ketone linkage is formed between an amino group and a 1,3-dicarbonyl group; thus, a precursor comprising an amino group can be conjugated to a solid support comprising a 1,3-dicarbonyl group, or a precursor comprising a 1,3-dicarbonyl group can be conjugated to a solid support comprising an amine group.
• the R 1 , R 2 , R 5 , or B groups in the intermediate independently may comprise optionally protected amine, optionally protected carboxylic acid, optionally protected thiol, maleimide, alkyne, or azide groups to allow for conjugation with solid supports.
• the R 1 , R 2 , R 5 , or B groups independently may optionally be substituted by solid supports connected via carboxylic amide, thioether, or 1,2,3-triazole groups.
• the intermediate may be attached to the surface via a multi-valent carrier, such as a dendrimeric or branched carrier.
• linkages may be through dendrimers or polyvalent macromolecules coupled to the compound of formula (5) or drug conjugates. This is described in the copending application filed under attorney docket number 67057-20004.00, which is hereby incorporated by reference. The intermediate or drug conjugate is therefore coupled through the dendrimer to the solid support.
• a dendrimer is prepared which comprises a group on the dendrimer that may be selectively coupled to a suitable-modified metallic surface.
• Suitable groups for such selective coupling include groups such as azides, terminal alkynes, cycloalkynes, thiols, and maleimido groups.
• a dendrimer may be prepared by solid-phase synthesis starting from a protected cysteine-resin. Successive rounds of coupling with di-Fmoc-lysine generate a dendrimeric structure. A final round of couplings is performed using Fmoc-L-azidonorleucine. The final Fmoc is removed, and the free amine groups are reacted with a polyethylene glycol activated as its N-hydroxysuccinimide (NHS) ester.
• NHS N-hydroxysuccinimide
• the resulting PEGylated dendrimer is then coupled to an alkyne-drug conjugate using Cu(I)-catalysis, and the PEG-dendrimer-drug conjugate is cleaved from the resin using trifluoroacetic acid.
• the resulting complex comprises a free thiol at the core cysteine, which may be coupled to a maleimido-modified surface prepared as described above.
• the final round of couplings uses di-Fmoc-lysine; removal of the Fmoc groups, coupling of the dendrimer to linker-drug using any of the above- described methods, and cleavage from the synthesis resin provides a non-PEGylated dendrimer which may be coupled to a maleimido-modified surface.
• a functional group on the intermediate is attached directly to a compatible functional group on the solid support.
• a functional group on the intermediate is reacted with a linking group attached to the solid support, e.g., a
• hydroxyl groups on a stent or other medical device coated with a hydroxylated polymer such as poly(ethylene-co-vinyl alcohol) (EVAL)
• EVAL poly(ethylene-co-vinyl alcohol)
• Conjugation of the intermediates of the present invention to medical devices coated with other functionalized polymers such as carboxylated polymers or amino polymers, including, e.g., poly(vinylamine) (PVA), poly(ethyleneimine) (PEI), poly(N-methyl-ethylene imine) (PMEI), and poly(amino-amines) (PAA), may also be envisioned to react with suitably functionalized intermediates.
• PVA poly(vinylamine)
• PEI poly(ethyleneimine)
• PMEI poly(N-methyl-ethylene imine)
• PAA poly(amino-amines)
• a stent coated with the hydroxylated polymer may be activated and reacted with a linking moiety, such as a functionalized PEG, to install a different functional group that may be compatible with other intermediates.
• a linking moiety such as a functionalized PEG
• reaction of the activated hydroxyl groups with an amino-PEG moiety provides a polymer-coated stent conjugated to PEG via a urethane linkage.
• the free hydroxyl groups of the PEG moiety can be further reacted, e.g., with a propargylic halide, to install a terminal acetylene group that can undergo cross-coupling with an azide on the intermediate molecule.
• the intermediate molecules can be conjugated to materials such as surgical gauzes, surgical sutures (monofilaments, twisted yarns or knitting yarns), absorbent pads, bandages, burn dressings and packings for tooth cavities in the form of cotton, paper, woven or non-woven fabrics, sponges, and the like, which may comprise either natural polymers (e.g.
• cellulose viscose rayon, cellulose acetate, carboxymethyl cellulose, methyl cellulose, agarose, dextran, pectin, alginic acid, chitin, polysaccharides, and proteins such as wool, silk, collagen, galatin and casein), which contain functional groups such as free hydroxyl groups, amines or carboxylic acids.
• a wide variety of synthetic polymers may also be used.
• hydroxyl group-containing polymeric materials such as cotton or cellulose
• the hydroxylated material can be activated with a variety of other reactive materials to install different functional groups.
• acylation with bromoacetyl bromide gives a bromoacetyl group that can react with amine-, hydroxyl- or thiol- containing intermediates.
• the hydroxylated material can be reacted with a polyaldehyde, such as glutaraldehyde or glyoxal, to introduce formyl groups which can undergo reaction with amine-containing intermediates.
• the intermediate molecules can be conjugated to proteinaceous materials such as collagens, which can optionally be in the form of collagen hydrogels, including those commonly used in eyedrops and eardrop.
• proteinaceous materials such as collagens, which can optionally be in the form of collagen hydrogels, including those commonly used in eyedrops and eardrop.
• thiolation of collagen can be accomplished under standard conditions.
• the surface thiol groups can be further reacted with activating agents, such as carbonyldiimidazole, and then reacted with an amine containing intermediate to provide a thiocarbamate-linked collagen drug conjugate.
• the thiol groups can be alkylated with, e.g., a propargylic halide, to give terminal acetylene groups that can react with azide containing intermediates.
• Coupling may also be through acylation of amino groups on the collagen.
• R 1 , R 2 and R 5 are as above-defined or alternatively, one of R 1 , R 2 and R 5 is coupled to a solid support.
• the resulting compound comprises a carbamate linkage.
• the amino group that reacts with the intermediate may be a terminal alpha-amino group or the amino group of a side-chain, for example of a lysine, ornithine, or unnatural amino acid residue.
• the activating reagent may be a substituted phenyl chloroformate, for example, 4-nitrophenyl chloroformate, 2,4-dinitrophenyl chloroformate, or pentafluorophenyl chloroformate, resulting in formation of an intermediate substituted phenyl carbonate.
• the precursors wherein the drug is an oligonucleotide or nucleic acid may be prepared by chemical synthesis of the drug comprising a 5 '-terminal modification that allows for conjugation.
• the oligonucleotide may be chemically synthesized such that the 5 '-terminal nucleotide unit, added at the last round of synthesis, comprises a phosphate group modified to contain an amino-alkyl group.
• the resulting amine-modified nucleic acid molecule is then conjugated to form a drug conjugate. See, for example, Zhao, et al, Bioconjugate Chemistry (2005) 16(4):758-766.
• the intermediate formed by reaction with an amino acid is then employed in standard peptide synthesis, for example: peptide
• the intermediate is attached during the synthesis of the peptide.
• the final step in the synthesis of the peptide by solid-phase peptide synthesis methods well-known in the art involves attachment of the N-terminal amino acid of the sequence of the peptide in protected form. Applying this technology to the present compounds, after deprotection of the final amino acid residue, the activated linker is coupled to the support- bound peptide. Final deblocking and removal from the synthesis resin provides the N- terminally linked peptide:
• This embodiment is advantageous in that the position and stoichiometry of derivitization is completely controlled.
• a suitable reducing agent for example NaBH 4 or NaBH 3 CN
• R 1 R 2 CH 2 is fluorene
• this is reacted with a strong base, for example, to form a fluorenyl carbanion, which is then reacted with R 5 2 -CO
• the reaction is as follows:
• a strong base such as NaH, butyllithium, lithium bis(trimethyl-silylamide), or similar
• Analogs wherein L is another suitable leaving group, such as a tosylate, mesylate, iodide, or R 2 S + are prepared using methods known in the art.
• L* is a chloride donor such as Me 3 SiCl or HC1, yielding a compound wherein L is CI.
• Such intermediates can be reacted with a drug comprising OH, SH or a non- basic NH group under anhydrous conditions in the presence of mild base.
• Suitable bases include tertiary amines, such as triethylamine and ⁇ , ⁇ -diisopropylethylamine, pyridine, or 4- (dimethylamino)pyridine.
• the reaction mixture may optionally include Nal or a
• Suitable solvents include any inert, anhydrous solvent, including tetrahydrofuran, acetonitrile, dimethylformamide, ethyl acetate, dichloromethane, acetone, and chloroform.
• the drug comprises a phenol or non-basic NH
• a strong base for example NaH, lithium bis(trimethylsilylamide), lithium diisopropylamide, or similar.
• the solid supports may also include protective polymer (the most common example would be polyethylene glycol (PEG), but other hydrophilic polymers could also be used).
• the protective polymer is a PEG of average molecular weight between 2,000 and 20,000 Daltons, preferably between 2,000 and 10,000 Daltons, and more preferably between 2,000 and 5,000 Daltons.
• the PEG is a monomethoxy-PEG.
• pre-assembled units comprising a PEG, a releasable linker, and a drug, or some combination of these units are prepared, then the pre-assembled units are attached to the solid support.
• Such pre-assembled units may be constructed in a stepwise process starting from a trifunctional matrix molecule wherein each functionality may be selectively attached to a PEG, the releasable linker or the drug conjugate, and to the solid support.
• Suitable functionalities on the tri- or multi-functional matrix molecule include carboxylic acids, amines, maleimides, azides, thiols, and alkynes, which may be present in protected form.
• an amino acid comprising a carboxylic acid group and two
• differentially protected functional groups can be converted into such a pre-assembled unit by selective deprotection of one protected functional group, attachment of a PEG, then
• azidonorleucine is reacted with an activated PEG molecule, for example a PEG N-hydroxysuccinimide carbonate, so as to produce N a -PEG-azidonorleucine.
• N a -PEG- azidonorleucine is then either attached to the solid support through standard amide-forming reactions to provide a PEGylated solid support having an array of azide functionalities on the outer shell that can be subsequently coupled with alkynyl-linkers or alkynyl-drug conjugates, or is first reacted with an alkynyl-linker or alkynyl-drug conjugate under Cu(I) catalysis to provide the complete pre-assembled unit, which is then attached to a solid support derivatized with amine groups using standard amide-forming reactions.
• a protected cysteine for example S-(monomethoxytrityl)- cysteine
• an activated PEG molecule for example a PEG N-hydroxysuccinimide carbonate
• N a -PEG-S(mmt)-cysteine is attached to a solid support derivatized to amines using standard amide forming reactions, and the resulting solid support can be detritylated using mild acid and the resulting thiols reacted with a maleimide-linker or maleimide-drug conjugate.
• N a -PEG-S(mmt)-cysteine can be reacted with an amine-linker or amine drug conjugate using standard amide-forming reactions, and the complete pre-assembled unit can be detritylated using mild acid and coupled to a solid support derivatized to maleimide groups.
• the conjugates of the invention that are designed to release drugs at controllable rates are administered to subjects in a manner similar to medicaments in general.
• the subjects may be model systems such as mice, rats or rabbits or may be human patients or may be veterinary subjects such as companion animals, livestock, and avian subjects.
• the solid support conjugates may be administered by any of several methods, for example internally as surgical implants, subcutaneous implants, intraocular implants, suppositories, or coated medical devices such as stents, pacemakers, and heart valves, or externally as wound dressings or topical coatings.
• the dosage levels will depend on the nature of the drug, the condition to be treated, the nature of the subject, and the judgment of the attending professional.
• linker scaffolds having a range of functional groups as potential pK a modulators were designed, prepared and linked via carbamate bonds to N e -2,4-dinitrophenyl-L-lysine (N e -DNP-Lys) for evaluation of release rates.
• N e -DNP-Lys N e -2,4-dinitrophenyl-L-lysine
• DNP-Lys was chosen as the released moiety as is water soluble and is a strong chromophore to permit HPLC-UV analysis. This experiment demonstrates that the rate of carbamate cleavage is controllable through the choice of particular substituents on the trigger group.
• the dinitrophenyl (DNP) carbamates were prepared as follows. A suspension of N- DNP-L-Lys HC1 (35 mg, 0.1 mmol) in 600 ⁇ , of water was treated successively with 1.0 N NaOH (200 ⁇ ) and 1.0 M NaHC0 3 . A 0.1 M solution of the N-HS carbonate in acetonitrile (1.0 mL) was added to the stirred mixture to give a clear yellow solution. After 1 hr, the mixture was diluted with 10 mL water and loaded onto a Bond-ElutTM CI 8 extraction column (1 gm). The column was washed successively with water, 1% CF 3 C0 2 H/water, water, and 50% MeOH/water. The product was eluted with MeOH, then evaporated to give the product as a yellow glass.
• R x 4-chloro, H, 4-methyl, 4-methoxy, 2,4-dimethyl, and 2,4,6-trimethyl;
• R y -(CH 2 ) 3 C ⁇ CH, -(CH 2 ) 5 N 3 , -(CH 2 ) 2 -maleimide
• stably conjugated Lys(DNP) was also prepared by click chemistry between Na-hexynoyl-Lys(DNP)-OH and 40 kDa-PEG-azide and administered to rats as a control.
• Competitive ELISA for DNP-Lys using DNP-BSA and an anti-DNP antibody conjugated to alkaline phosphatase is employed.
• triethylamine (1 equivalent) is added to a mixture of BNH 2 (1 equivalent) and the chloroformate (1 equivalent) in an inert anhydrous solvent, for example dichloromethane, tetrahydrofuran, or ethyl acetate. After stirring for 1 h at ambient
• N-Alkoxymethyl Carbamates N-Phenoxymethyl Carbamates, N-Thiomethyl Carbamates, and N-Thiophenylmethyl Carbamates
• Triethylamine (0.7 mL) was added to a stirred mixture of 4-bromoaniline (0.85 g) and 9-fluorenylmethoxycarbonyl chloride (1.3 g) in 25 mL of dichloromethane. The mixture was stirred for 1 h at ambient temperature, then washed with 1 N HCl, water, sat. aq. NaHC0 3 , and brine. The organic solution was dried over MgS0 4 , filtered, and evaporated.
• Triethylamine (0.7 mL) was added to a stirred mixture of ethyl 4-aminobenzoate (0.85 g) and 9-fluorenylmethoxycarbonyl chloride (1.3 g) in 25 mL of dichloromethane. The mixture was stirred for 1 h at ambient temperature, then washed with 1 N HCl, water, sat. aq. NaHC0 3 , and brine. The organic solution was dried over MgS0 4 , filtered, and evaporated.
• Step 1 N-(tert-butoxycarbonyl)-L-serine allyl ester: To a stirred solution of allyl bromide (2.3 mL, 26.6 mmol) and tricaprymethylammonium chloride (4.00 g, 9.90 mmol) in CH 2 C1 2 (35 mL) was added a solution of N-(tert-butoxycarbonyl)-L-serine (1.03 g, 5.02 mmol) and NaHC0 3 (0.43 g, 5.12 mmol) in water (16 mL). The biphasic reaction mixture was vigorously stirred at room temperature for 48 hours.
• Step 2 A solution of N-(tert-butoxycarbonyl)-L-serine allyl ester (0.175 g,
• Step 1 A solution of N-(6-(2,4-dinitrophenylamino)hexanoyl-L-serine allyl ester (0.050 g, 0.118 mmol), 0-(9-fluorenylmethyl) N-phenyl N-chloromethyl carbamate (0.043g, 0.1 18 mmol) and triethylamine (16.1 mL, 0.116 mmol) in anhydrous CH 2 C1 2 (2 mL) was heated at reflux for 1 hour.
• Step 2 Tetrakis(triphenylphoshine)palladium(0) (0.002 g, 1.7 ⁇ ) was added to a stirred solution of the allyl ester from Step 1 (0.030 g, 40 ⁇ ) and phenylsilane (9.8 mL, 80 ⁇ ) in anhydrous tetrahydrofuran (0.5 mL). The reaction mixture was stirred at ambient temperature for 30 minutes and was then concentrated. Silica gel and CH2CI2 were added and the mixture again concentrated and loaded onto a short silica gel column.
• a solution of fluorene-2-carbonyl chloride (prepared from fiuorene-2-carboxylic acid and oxalyl chloride) in THF is added to aqueous methylamine (2 molar equivalents) to prepare N-methyl fiuorene-2-carboxamide.
• Reduction of the amide using LiAlH 4 in ether provides 2-((methylamino)methyl)fluorene.
• the amine is protected by reaction with di-tert- butyl dicarbonate to provide 2-((N- t BOC-N-methylamino)methyl)fluorene.
• the carbamate is dissolved in trifluoroacetic acid to remove the 3 ⁇ 4OC protecting group. After evaporation to dryness, the resulting amine is dissolved in THF and treated with N-(6-azidohexanoyl)succinimide and triethylamine (2 equivalents) to provide 0-(9-(2-((N-(6- azidohexanoyl)-N-methylamino)methyl)fluorenylmethyl) N-phenylcarbamate.
• This example demonstrates the linkage of a drug molecule with the compounds of the invention, particularly through a phenol group in the drug molecule.
• N 3 (CH 2 ) n C0 2 R' (n 3-6) in the presence of a strong base, for example NaH, lithium bis(trimethylsilyl)amide (LiHMDS), or lithium diisopropylamide (LDA), provides a ketone which is reduced to the alcohol by reaction with a mild reductant, for example sodium borohydride in methanol. The resulting alcohol is then converted into the carbamate via the chloroformate, and then into the N-chloromethylcarbamate as described above.
• a strong base for example NaH, lithium bis(trimethylsilyl)amide (LiHMDS), or lithium diisopropylamide (LDA)
• LiHMDS lithium bis(trimethylsilyl)amide
• LDA lithium diisopropylamide
• the resulting amine is coupled with a macromolecule comprising a carboxylic acid using a condensing agent, for example a carbodiimide such as EDCI.
• a condensing agent for example a carbodiimide such as EDCI.
• An ethyl (2-phenylsulfonyl)acetate is deprotonated using excess NaH in THF and alkylated with N-(6-bromohexyl) ethyl carbamate.
• the product is reduced using lithium aluminum hydride in ether to provide the methylamino alcohol, which is N-protected as the BOC carbamate.
• the alcohol is converted to the chloroformate and thence into the carbamate and into the N-chloromethyl carbamate according to the previous procedures.
• a phenyl methylsulfone is deprotonated with NaH in tetrahydroiuran, rhen acylated with glutaric anhydride to provide a keto-acid.
• the resulting acid is protected as the tert-butyl ester, and the ketone is reduced using NaB3 ⁇ 4.
• the resulting alcohol is converted into the carbamate via the chloroformate, and thence to the N-chloromethyl carbamate as described above.
• CCK8 (Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH 2 ) is synthesized on solid support using Rink resin using methods known in the art, for example as described in US Patent 4,769,445 (incorporated herein by reference).
• Commercial Fmoc-Phe-Rink amide- MBHA resin is pre-swollen in DMF for 30 min, then suspended and shaken in piperidine/DMF (1 :4 by volume, 50 ml) for 30 min at room temperature to remove the Fmoc group.
• Phe- Rink amide- MBHA resin (1 meq) is suspended in the filtered reaction mixture (precipitated DCU removed) and shaken for 2 to 15 hours at room temperature.
• the Fmoc-Asp-(O l Bu)-Phe- Rink amide- MBHA resin product is collected by filtration and washed with DCM.
• the Fmoc-Asp-(O l Bu)- Phe- Rink amide-MBHA resin is suspended and shaken in piperidine/DMF (1 :4 by volume, 50 ml) for 3 min at room temperature and then a second time for 7 min to remove the Fmoc group.
• the Fmoc-Met-Asp-fO'B ⁇ -Phe-Rink amide-MBHA resin product is collected by filtration and washed with DCM and DMF.
• the Fmoc-Met-Asp- (O l Bu)-Phe- Rink amide-MBHA resin is deprotected and coupled sequentially with Fmoc-Trp- OH (1.28 g, 3 mmol), Fmoc-Gly-OH (0.89 g, 3 mmol), Fmoc-Met-OH (1.12 g, 3 mmol), Fmoc- Tyr-OH (1.37 g, 3 mmol), and Boc-Asp ⁇ B ⁇ -OH (1.23 g, 3 mmol) to provide Boc- Asp ⁇ B ⁇ -Tyr-Met-Gly ⁇ -Met-Asp ⁇ tBu Phe-Rink amide-MBHA resin.
• the Boc- Asp(O t Bu)-Tyr-Met-Gly-Trp-Met-Asp(O t Bu)-Phe-Rink amide-MBHA resin is washed with DCM (3x50 ml), suspended and shaken in a mixture of 0-(9-fluorenylmethyl) N-phenyl N- chloromethylcarbamate (10 equivalents) and triethylamine (1 equivalent) in DCM.
• the resin is isolated by filtration and washed (3 50 ml each) with DCM.
• the resulting Boc-Asp(O l Bu)- Tyr(OX)-Met-Gly-Trp-Met-Asp(OtBu)-Phe-Rink amide-MBHA resin is cleaved from the resin and deblocked by shaking with a mixture of 8% phenol, 5% thioanisole, 5% water, and 3% 3,6-dioxa-l,8-octanedithiol in trifluoroacetic acid (10 mL/g resin) for 4 hours.
• the resin is removed by filtration, and the peptide is precipitated by addition of 10 volumes of ether.
• the crude peptide is purified by reversed-phase HPLC.
• cysteine-containing peptide is prepared by solid phase synthesis using the methods described above, incorporating an
• cysteine residue Prior to cleavage from the resin, the cysteine residue is selectively deblocked using (Ph 3 P) 4 Pd and phenylsilane in DCM, then reacted with a compound of formula (3) as described above. The peptide is finally deblocked, removed from the resin, and purified as described above.
• linker-drug compounds of formula (1) may be prepared from 5-fluorouracil and a compound of formula (3) (before or after connection of the linker to a solid support) analogously to the procedures used by Taylor and Sloane, "1- Alkylcarbonyloxymethyl Prodrugs of 5-Fluorouracil (5-FU): Synthesis, Physicochemical Properties, and Topical Delivery of 5-FU", J. Pharmaceutical Sci.
• the filtrate is allowed to react with a mixture of 1- (allyloxycarbonyl-oxymethyl)-5-fluorouracil [Liu, Fullwood, and Rimmer, "Synthesis of Allyloxycarbonylmethyl-5-fluorouracil and copolymerizations with N-vinylpyrrolidinone", J Materials Chem. 10: 1771-7, 2000] (0.8 mmol) and l,8-bis(dimethylamino)naphthalene at ambient temperature. After 6 h, the mixture is diluted with ether, stirred for 1 h, and filtered.
• the filtrate is concentrated to provide the crude protected product, which is treated with a mixture of tetrakis(triphenylphosphine)-palladium(0) and phenylsilane in anhydrous THF for 1 h to remove the allyloxycarbonylmethyl protecting group.
• the mixture is evaporated, and the residue is purified by silica gel chromatography to provide the linker-drug compound of formula (1) where the drug-linker moiety is ready for attachment to the solid support.
• 6-Azido-l-hexanol a mixture of 6-chloro-l-hexanol (25 g, 183 mmol) and sodium azide (32.5 g, 500 mmol) in 200 mL of water was heated at reflux for 20 h, then cooled to ambient temperature and extracted 3x with ethyl acetate. The combined extracts were washed with brine, dried over MgS0 4 , filtered, and concentrated to yield the product as a pale yellow oil (28.3 g).
• 6-Azidohexanal Solid trichloroisocyanuric acid (TCCA; 4.3 g) was added in small portions to a vigorously stirred mixture of 6-azido-l-hexanol (7.15 g) and sodium bicarbonate (5.0 g) in dichloromethane (100 mL) and water (10 mL). The mixture was stirred for an additional 30 minutes after addition, then filtered through a pad of diatomaceous earth. The organic phase was separated and washed successively with sat. aq. NaHC0 3 and brine, then dried over MgSC ⁇ , filtered, and concentrated to provide the product (5.8 g), which was used without further purification.
• TCCA Solid trichloroisocyanuric acid
• Compounds prepared according to this method include:
• R-CH 3 phenyl methyl sulfone
• R-CH 3 4-methylphenyl methyl sulfone
• R-CH 3 4-acetylmorpholine
• R-CH 3 " fluorene
• 6-azidohexyl chloroformate was prepared as described above, starting from 6-azidohexanol. The control system cannot undergo beta-elimination.
• the crude HSE carbonate was first chromatographed on silica gel using a gradient of ethyl acetate in hexane, followed by crystallization. All compounds were crystalline with the exception of that obtained from 1 - (methanesulfonyl)-7-azido-2-heptanol.
• Compounds prepared according to this method include:
• DBCO-sulfoNHS ester was prepared according to Staros, J.V., Biochemistry 1982, 21, 3950-3955. A solution of 0.88 M dicyclohexylcarbodiimide in DMF (250 ⁇ ,) was added to a suspension of 43.4 mg sodium N-hydroxysulfosuccinimide (200 ⁇ ; Thermo Scientific) and 78.1 mg DBCO-acid (200 ⁇ ; Click Chemistry Tools) in 250 xL DMF in a 1.5 mL microcentrifuge tube.
• the mixture was incubated 16.5 hr at RT on a Daigger Vortex Genie 2 (vortex setting 3), during which time the sodium N-hydroxysulfosuccinimide dissolved and another precipitate formed.
• the suspension was centrifuged (14,000 rpm, 10 min) and the supernatant transferred to a 50 mL centrifuge tube. The washes were pooled with the original supernatant to give a total volume of 1.3 mL. Ethyl acetate (30 mL) was added, and a precipitate was allowed to form over 1 hour. The precipitate was collected by centrifugation (4000 rpm, 10 min).
• the pellet washed successively with 20 mL of ethyl acetate (2x) and 15 mL of ethyl ether (3x), then dried giving a yield of 89.1 mg (151 ⁇ ).
• the resin (5.8 ⁇ of DBCO; 0.2 to 6.2 ⁇ of amine) was suspended in 3 mL of 0.25 M HEPES, pH 7.5, and 0.5 mL of 0.4 M acetic anhydride in acetonitrile (200 ⁇ ) was added and agitated for 1 hr.
• the resin was washed with 5 mL of 0.25 M HEPES, pH 7.5, followed by 5 mL of 0.1 M HEPES, pH 7.5.
• the solvent was exchanged by successively washing with 2 mL each of 25%, 50%, and 75% MeOH in 0.1 M HEPES, pH 7.5, followed by 10 mL of 100% MeOH.
• the resin was stored in MeOH at 0-4°C.
• PEGA a beaded copolymer of polyethylene glycol and dimethylacrylamide
• DBCO a beaded copolymer of polyethylene glycol and dimethylacrylamide
• the mixture was agitated by constant end-over-end turning on a Hematology/Chemistry Mixer (Fisher). As the reaction progressed, a 10 aliquot obtained from drops released at the outlet was diluted with 760 ⁇ . of H 2 0, acidified with 30 ⁇ , of 0.2 M acetic acid, pH 3.5, to remove absorbance of the NHS, and used to determine remaining soluble DBCO by UV measurements (the unused portion of the aliquot was returned to the reaction). After 4 hrs, the amount of soluble DBCO remained constant.
• the resin was sequentially washed with 4 mL of 0.1 M HEPES, pH 7.5, 2.5 mL of 1 M NaCl, and 2.5 mL of 0.1 M HEPES, pH 7.5. The combined washings were acidified with an equal volume of 0.2 M acetic acid, pH 3.5, and UV
• the resin was equilibrated with 1 :1 MeOH/0.1 M HEPES, pH 7.5, converted to a 2 mL slurry, treated with 0.6 mL of 61.5 mM acetyl-N-hydroxysuccinimide in 1 :1 MeOH/0.1 M HEPES, pH 7.5 (36.9 ⁇ ) and agitated for 2 h.
• the resin was washed with 5 mL of 0.25 M HEPES, pH 7.5, followed by 5 mL of 0.1 M HEPES, pH 7.5.
• the resulting resin was washed with methanol (7.5-10 mL) to remove unbound fluorescein; the combined washes were analyzed for fluorescein content by measurement of the absorbance at 492 nm after dilution into 0.1 M sodium borate. Bound fluorescein was determined by the difference between the total fluorescein adding in the reaction and the unbound measured after resin washing. The column was drained of excess methanol, and the wet resin was stored at 4°C.
• control R H (containing 1.12 ⁇ packed resin).
• Example 32 The conjugate of Example 32 (20-30 nmol of total fluorescein) was suspended in 1 mL of 0.1 M bicine, pH 8.45, 37°C, in a 1.5 mL microfuge tube and agitated on a rotating rocker (Clay-Adams Nutator) in a 37°C incubator. At intervals the suspension was centrifuged, the optical density at 492 nm of the supernatant was determined, and the supernatant returned to the vessel.
• 0.1 M bicine pH 8.45, 37°C
• a rotating rocker Clay-Adams Nutator
• Metal surfaces modified with amine, carboxylate, azide, alkyne, thiol, or maleimide groups are prepared as follows.
• Amine-modified titanium surfaces are prepared according to the procedure of Xiao, et ah, Langmuir 14: 5507-5516 (1998).
• a titanium surface is pretreated using water vapor plasma using a plasma cleaner/sterilizer such as a PDC-32G (Harrick, New York) at 0.42 mbar for 2 minutes, then vacuum dried.
• the dried surface is treated with a 1% (w/v) solution of (3-aminopropyl)triethoxysilane in toluene for 48 h at 80°C.
• the surface is then ultrasonically washed five times using chloroform, twice with acetone, and five times with methanol, then rinsed with water and vacuum dried and cured at 100°C for 1 h under N 2 .
• the amine-modified titanium surface is used to make the carboxylate-modified surface by treatment with a cyclic anhydride, for example succinic anhydride or glutaric anhydride.
• a cyclic anhydride for example succinic anhydride or glutaric anhydride.
• the amine-modified titanium surface is suspended in a solution of 0.1 M succinic anhydride in acetonitrile, and triethylamine is added to a final concentration of 0.1 M. After 12 h, the titanium surface is removed and washed and dried as described above.
• the amine-modified titanium surface is used to make the azide-, alkyne-, and maleimide-modified surfaces by reaction with the appropriate N-hydroxysuccinimide ester of an azide-, alkyne-, or maleimide-substituted carboxylic acid, for example
• N-(6-azidohexanoyloxy)succinimide in acetonitrile, and triethylamine is added to a final concentration of 0.1 M.
• the titanium surface is removed and washed and dried as described above to provide an azide-modified titanium surface.
• an amine-modified titanium surface is suspended in a solution of 0.1 M N-(3-
• the amine-modified titanium surface is used to make the thiol-modified titanium surface by reaction with the NHS ester of an appropriate blocked-thiol reagent. For example, an amine-modified titanium surface is suspended in a solution of 0.1 M N-(3-(2- pyridyldithio)propionyloxy)succinimide in the presence of 0.1 M triethylamine. After 1 h, the titanium surface is removed and washed and dried as described above to provide a
• 2-pyridyldithio-modified titanium surface Prior to use, the 2-pyridyldithio-modifled titanium surface is suspended in a 10 mM solution of tris(2-carboxyethyl)phosphine hydrochloride in 0.1 M MES buffer, pH 6. The solution is analyzed for formation of 2-pyridyIthione by monitoring the absorbance at 343 nm. When the absorbance reaches a maximum, the titanium surface is washed and dried as described above to provide a thiol-modified titanium surface.
• modified surfaces are prepared starting with other metals having free surface hydroxyl groups, for example stainless steel, cobalt-chrome alloys, and cobalt- chromium-molybdenum alloys.
• Collagen is treated to introduce functional groups as follows.
• Insoluble Type I collagen is prepared following the procedure of Tiller, et al, Biotechnol. Bioengineering (2001) 73:246-252. Thus, the collagen is soaked overnight in 0.5 M acetic acid at 4°C, then
• the collagen is suspended at 1% in 0.1 M phosphate buffer, pH 7.4, and placed under vacuum to remove entrapped air bubbles.
• collagen modified by azide, alkyne, or maleimide groups is prepared by treatment with the corresponding sulfosuccinimidyl reagent.
• modified collagens are made into collagen films by dilution with 0.5 M acetic acid to 2.5 mg/mL, applying one mL of this to a petri dish and allowing it to dry thoroughly to form a transparent film.
• the films are washed with 10 mM phosphate buffer, pH 7.4, for 3 h, then with water for 2 h, and dried.
• underivatized collagen may be treated as described above to introduce the various functional groups.
• Hydrogels are cross-linked polymer gels, such as calcium alginate, sodium polyacrylate, polyvinyl alcohol, polyacrylamide, polyethyleneoxide, and polyvinyl pyrrolidone, consisting of a network of polymer chains that are water-insoluble, sometimes found as a colloidal gel in which water is the dispersion medium.
• Hydrogels are highly absorbent (they can contain over 99% water) natural or synthetic polymers. Hydrogels also possess a degree of flexibility very similar to natural tissue, due to their significant water content. They may be shaped into sheets to provide and maintain a moist wound environment conducing to maximal healing. By increasing moisture content, hydrogels have the ability to help clean and debride necrotic tissue. Hydrogels are non-adherent and can be removed without trauma to the wound.
• Various hydrogel dressings are commercially available as sheets, for example calcium alginate prepared as a textile fiber called TegaGel® (3M) and sodium polyacrylate called
• Alginate- and polyacry late-based hydrogels may be modified through derivitization of free carboxylate groups using a carbodiimide condensing reagent, for example EDCI, in the presence of N-hydroxysuccinimide to provide alginate comprising activated
• a carbodiimide condensing reagent for example EDCI
• N-hydroxysuccinimide esters The activated alginate is then coupled with an amine compound that also comprises the desired functional group, for example azide, amine, alkyne,
• Cellulosic materials such as cotton, surgical gauzes, surgical sutures, absorbent pads, bandages, burn dressings, and packings for tooth cavities in the form of cotton, paper. Fabrics, sponges, and the like, which contain free hydroxyl groups may be modified in various ways.
• the material is treated with a polymaleic anhydride or a poly(maleic anhydride-co-vinyl acetate) to introduce carboxylate functional groups.
• the copolymer is prepared by radical copolymerization of maleic anhydride and vinyl acetate as described in Xiao, et al, "Synthesis and properties of starch-g-poly(maleic anhydride-co-vinyl acetate)," Express Polymer Letters 4:9-16 (2001).
• a mixture of the cellulosic material and copolymer in water is heated to 100°C to drive off the water.
• the resulting material is washed thoroughly with ethanol and dried to provide carboxylate-modified cellulosic material.
• the resulting carboxylated cellulosic material is activated by reaction with a carbodiimide condensing reagent, for example EDCI, in the presence of N-hydroxysuccinimide to provide modified cellulose comprising activated N-hydroxysuccinimide esters.
• a carbodiimide condensing reagent for example EDCI
• the activated cellulose is then coupled with an amine compound that also comprises the desired functional group, for example azide, amine, alkyne, 2-pyridyldithiol, or maleimide.
• an alkyne-modified cellulosic material the activated cellulosic material would be reacted with an alkynylamine, for examine 5-hexyn-l -amine.
• An alkyne-modified titanium surface prepared as described in Example 34 is suspended in a 0.1 M solution of the linker-SN-38 compound of Example 13 in tetrahydrofuran.
• a catalyst mixture comprising 50 mM CuS0 4 , 50 mM tris-[(l-benzyl-lH-l ,2,3-triazol-4- yl)methyl]amine (TBTA) and 100 mM sodium ascorbate is added, and the reaction is allowed to proceed for 48 h.
• the titanium surface is removed, ultrasonically washed five times using chloroform, twice with acetone, and five times with methanol, then rinsed with water and vacuum dried and cured at 100°C for 1 h under N 2 .
• Antibody releasably attached to a modified collagen
• the antibody is activated on a surface amine group by reaction with a releasable linker comprising an azido group and an N-hydroxysuccinimidyl carbonate prepared as described in co-pending application published as WO2009/158668 and as described above.
• a solution of the antibody at 2 mg/mL of 0.1 M NaHC0 3 , pH 8.4 is treated with a solution of the azide-linker-NHS in DMSO for 4 hrs at ambient temperature.
• the resulting mixture is dialyzed against PBS, pH 7.4, to remove excess reagents and provide a solution of the antibody attached to the azide-linker via a carbamate group.
• An alkyne-modified collagen prepared as described in Example 35 is suspended in a solution of the azide linker-antibody compound in PBS.
• a catalyst mixture comprising 50 mM CuS0 4 , 50 mM tris-[(l -benzyl-lH-l,2,3-triazol-4-yl)methyl]amine (TBTA) and 100 mM sodium ascorbate is added, and the reaction is allowed to proceed for 48 h.
• the collagen is removed and washed thoroughly with water to provide the antibody releasably attached to collagen.
• Growth factors or cytokines may be releasably attached to solid supports such as metal surfaces, collagens, hydrogels, and cellulosic materials.
• a growth factor such as platelet-derived growth factor (PDGF)
• PDGF platelet-derived growth factor
• the growth factor is activated on a surface amine group by reaction with a releasable linker comprising an azido group and an N-hydroxysuccinimidyl carbonate prepared as described in co-pending application published as WO2009/158668, and as described above.
• a solution of the growth factor at 2 mg/mL of 0.1 M NaHC0 3 , pH 8.4 is treated with a solution of the azide-linker-NHS in DMSO for 4 hrs at ambient temperature.
• the resulting mixture is dialyzed against PBS, pH 7.4, to remove excess reagents and provide a solution of the growth factor attached to the azide-linker via a carbamate group.
• An alkyne-modified surgical gauze prepared as described in Example 37 is suspended in a solution of the azide linker-growth factor compound in PBS.
• a catalyst mixture comprising 50 mM CuS0 , 50 mM tris-[(l-benzyl-lH-l,2,3-triazol-4-yl)methyl]amine (TBTA) and 100 mM sodium ascorbate is added, and the reaction is allowed to proceed for 48 h.
• the collagen is removed and washed thoroughly with water to provide the growth factor releasably attached to surgical gauze.
• a polymer-coated stent is prepared by a modification of the procedure described in WO2006/102247.
• EVAL Poly(ethylene-co-vinyl alcohol)
• 1 :1 DMSO:DMAC Poly(ethylene-co-vinyl alcohol)
• the 2% solution of the polymer is applied to a 13 mm TETRA ® stent in a series of 10-second passes, to deposit 10 ⁇ g of coating per spray pass. Between the spray passes, the stent is dried for 10 seconds using a flow of air at 80°C. Five spray passes are applied to form a 50 ⁇ g primer layer, followed by baking the primer layer at 140°C for one hour.
• the hydroxyl groups of EVAL are activated with carbonyldiimidazole and reacted with PEG-N3 ⁇ 4 to give a PEG-EVAL conjugate linked by a urethane moiety.
• the precursor compound of the invention is coupled to the activated hydroxyl groups in a separate reaction. These may be reacted with propargyl bromide and triethylamine in DMF solution to provide a PEG-EVAL conjugate containing a terminal alkyne. The alkyne is reacted with the intermediate containing an azidoalkyl group in R 1 , R 2 , R 5 or B. Drug may be coupled before or after this reaction.
• This polymer is dissolved in a 1 : 1 DMSO:DMAC to give a 2% by weight solution.
• the same apparatus used to spray the primer layer on the stent is used to apply the drug layer. Seventy spray passes are performed to form a 700 g drug-polymer layer, followed by drying the drug-polymer layer at 50°C for 2 hours.
• a topcoat layer comprising 2% by weight solution of poly(ethylene-co-butyl vinyl ether-co-vinyl alcohol) in 4: 1 DMAC:pentane is applied over the drug-containing layer using the same apparatus. Fifteen spray passes are performed to form a 150 g topcoat layer, followed by drying at 50°C for 2 hours.
• a finish coat layer comprising 2% by weight of poly(ethylene-co- mPEG(560)urethane-co-vinyl alcohol) in a 5:3:2 solution of DMAC:ethanol:DMSO is applied in a manner identical to the application of the previous layers. Thirty-five spray passes are performed to form a 350 ⁇ g finishing coat layer, followed by drying at 50°C for 2 hours.
• Nitinol (TiNi) is thin-coated with DLC using 13.56 MHz RF plasma-assisted chemical vapor deposition (PACVD).
• the DLC layers are deposited under a bias voltage of 400 V and deposition pressure of 1.33 Pa.
• the surface of TiNi-DLC is treated to remove impurities and the samples are vacuum-dried for 24 h to obtain an oxidized TiNi-DLC.
• Alkynyl PEG is isocyanated by a modification of known procedures. Id.
• Alkynyl PEG is reacted with 0.2% dibutyltin dilaurate (DBTDL) and hexamethylene diisocyanate (HDI) (2 eq.) dissolved in toluene under nitrogen at 45°C for 45 min.
• DBTDL dibutyltin dilaurate
• HDI hexamethylene diisocyanate
• TiNi-DLC samples are grafted with alkynyl-PEG isocyanate and stannous octoate in toluene at 40°C for 24 h to produce PEG-grafted TiNi-DLC.
• the TiNi-DLC-PEG is reacted with a conjugate containing an azidoalkyl linker, via Huisgen's 1,3-dipolar
• Drug may be coupled before or after this reaction.
• Surgical gauze (cotton made, 5 cm x 5 cm) is reacted with polymaleic anhydride dissolved in acetone at a concentration of about 10% by weight, optionally containing catalytic hydrochloric acid, and the mixture is reacted for 10 hours at 25°C, as generally described in U.S. Patent No. 4,265,233.
• the polymer-impregnated gauze is reacted with N-hydroxysuccinimide (NHS) and DCC in DMF for 3 hours at 25°C.
• NHS-activated acid is reacted with the intermediate compound containing an amine linker. Drug may be coupled before or after this reaction.
• DBC Dermal bovine collagen
• the thiolated DBC is reacted with carbonyldiimidazole and triethylamine in DMF, followed by reaction with an intermediate containing an amine in the R 1 , R 2 , R 5 or B functional group to provide a thiocarbamate-linked collagen conjugate.
• Drug may be coupled before or after this reaction.
• the thiolated DBC is reacted with NHS-activated 3-butynoic acid in DMF.
• the alkyne containing product is further reacted with a drug conjugate containing an azidoalkyl linker, via Huisgen's 1,3-dipolar cycloaddition catalyzed by copper sulfate.
• Example 45
• the surface of the medical device is grafted with a vinyl containing polymer, such as a hydroxy-functional PVP copolymer (e.g., as described in U.S. Patent No. 3,563,968), using eerie ion initiation (CelV), ozone exposure or UV irradiation, as generally disclosed in U.S. Patent No. 6,033,719.
• a vinyl containing polymer such as a hydroxy-functional PVP copolymer (e.g., as described in U.S. Patent No. 3,563,968), using eerie ion initiation (CelV), ozone exposure or UV irradiation, as generally disclosed in U.S. Patent No. 6,033,719.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Epidemiology (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Pharmacology & Pharmacy (AREA)
• Molecular Biology (AREA)
• Heart & Thoracic Surgery (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Materials Engineering (AREA)
• Hematology (AREA)
• Surgery (AREA)
• Vascular Medicine (AREA)
• Dermatology (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Transplantation (AREA)
• Medicinal Preparation (AREA)
• Materials For Medical Uses (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=44904089

Family Applications (1)

Country Status (6)

Cited By (16)

Families Citing this family (68)

Citations (14)

Family Cites Families (1)

• 2011
  • 2011-05-05 EP EP11778383.7A patent/EP2566334B1/en active Active
  • 2011-05-05 JP JP2013509279A patent/JP5964815B2/ja active Active
  • 2011-05-05 CN CN201180022343.2A patent/CN103025164B/zh active Active
  • 2011-05-05 WO PCT/US2011/035422 patent/WO2011140392A1/en not_active Ceased
  • 2011-05-05 US US13/696,300 patent/US8946405B2/en active Active
  • 2011-05-05 DK DK11778383.7T patent/DK2566334T3/en active
• 2016
  • 2016-03-15 JP JP2016050380A patent/JP6250723B2/ja active Active

Patent Citations (14)

Non-Patent Citations (17)

Also Published As

Similar Documents

Legal Events